These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 30318690)
21. The scientific and regulatory rationale for indication extrapolation: a case study based on the infliximab biosimilar CT-P13. Reinisch W; Louis E; Danese S Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():17-26. PubMed ID: 26395531 [TBL] [Abstract][Full Text] [Related]
22. An update on biosimilar drugs for inflammatory bowel disease. Schreiber S Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():1-3. PubMed ID: 26395529 [TBL] [Abstract][Full Text] [Related]
23. Biosimilar infliximab for inflammatory bowel disease: from concepts to clinical practice. Case study illustrated with CT-P13. Schreiber S; Panés J; Kwon B; Hong S; Peyrin-Biroulet L Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():5-15. PubMed ID: 26395530 [TBL] [Abstract][Full Text] [Related]
24. Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab After One Year in a Prospective Nationwide Cohort. Gonczi L; Gecse KB; Vegh Z; Kurti Z; Rutka M; Farkas K; Golovics PA; Lovasz BD; Banai J; Bene L; Gasztonyi B; Kristof T; Lakatos L; Miheller P; Nagy F; Palatka K; Papp M; Patai A; Salamon A; Szamosi T; Szepes Z; Toth GT; Vincze A; Szalay B; Molnar T; Lakatos PL Inflamm Bowel Dis; 2017 Nov; 23(11):1908-1915. PubMed ID: 28922253 [TBL] [Abstract][Full Text] [Related]
25. Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study. Smits LJ; Derikx LA; de Jong DJ; Boshuizen RS; van Esch AA; Drenth JP; Hoentjen F J Crohns Colitis; 2016 Nov; 10(11):1287-1293. PubMed ID: 27095751 [TBL] [Abstract][Full Text] [Related]
26. Switching from originator to biosimilar infliximab - real world data of a prospective 18 months follow-up of a single-centre IBD population. Høivik ML; Buer LCT; Cvancarova M; Warren DJ; Bolstad N; Moum BA; Medhus AW Scand J Gastroenterol; 2018 Jun; 53(6):692-699. PubMed ID: 29852793 [TBL] [Abstract][Full Text] [Related]
27. Short article: Switching to a infliximab biosimilar: short-term results of clinical monitoring in patients with inflammatory bowel disease. Binkhorst L; Sobels A; Stuyt R; Westerman EM; West RL Eur J Gastroenterol Hepatol; 2018 Jul; 30(7):699-703. PubMed ID: 29538037 [TBL] [Abstract][Full Text] [Related]
31. Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients. Eberl A; Huoponen S; Pahikkala T; Blom M; Arkkila P; Sipponen T Scand J Gastroenterol; 2017 Dec; 52(12):1348-1353. PubMed ID: 28838273 [TBL] [Abstract][Full Text] [Related]
32. A budget impact model for biosimilar infliximab in Crohn's disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia. Brodszky V; Rencz F; Péntek M; Baji P; Lakatos PL; Gulácsi L Expert Rev Pharmacoecon Outcomes Res; 2016; 16(1):119-25. PubMed ID: 26162458 [TBL] [Abstract][Full Text] [Related]
33. Biosimilar Drugs for Inflammatory Bowel Disease: Is Similar Good Enough? Allocca M; Fiorino G; Danese S Dig Dis Sci; 2017 Nov; 62(11):2964-2965. PubMed ID: 28776140 [No Abstract] [Full Text] [Related]
34. Letter: immunogenicity of infliximab originator vs. CT-P13 in IBD patients. Fiorino G; Correale C; Radice S; Allocca M; Furfaro F; Gilardi D; Nagore D; Del Rio L; Pascual J; Martínez A; Danese S Aliment Pharmacol Ther; 2017 Nov; 46(9):903-905. PubMed ID: 29023889 [No Abstract] [Full Text] [Related]
35. Clinical and scientific aspects related to biosimilars in inflammatory bowel diseases (IBD): position document of the Belgian IBD Research & Development Group (BIRD). Vermeire S; Louis E; Dewit O; Franchimont D; Moreels T; Ferrante M; Rahier JF; Van Hootegem P; De Vos M; Mana F; Baert F; Acta Gastroenterol Belg; 2015; 78(1):26-9. PubMed ID: 26118575 [No Abstract] [Full Text] [Related]